Welcome to the e-CCO Library!

DOP59: Development of a novel Ulcerative Colitis (UC) endoscopic activity prediction model using machine learning (ML)
Year: 2022
Source: ECCO'22
Authors: Colombel , J.F.(1);Rubin , D.(2);Schott , J.P.(3);Gottlieb , K.(4);Erisson , L.(5);Prucka , B.(6);Phillips , S.(5);Kwon , J.(7);Ng , J.(8);McGill , J.(4);
Created: Friday, 11 February 2022, 3:52 PM
DOP59: Evaluation of the efficacy of tofacitinib as maintenance therapy in patients with Ulcerative Colitis stratified by OCTAVE Sustain baseline endoscopic subscore
Year: 2021
Source: ECCO'21 Virtual
Authors: Lee, S.D.(1);Allegretti, J.R.(2);Steinwurz, F.(3);Connelly, S.B.(4);Lawendy, N.(4);Paulissen, J.(5);Gecse, K.B.(6)
Created: Wednesday, 2 June 2021, 4:12 PM
DOP59: Proactive infliximab drug monitoring is superior to conventional management in inflammatory bowel disease
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

S. Raimundo Fernandes*1, S. Bernardo1, C. Simões1, L. Correia1, P. Moura Santos1, A. Rita Gonçalves1, A. Valente1, C. Baldaia1, R. Tato Marinho1

Created: Friday, 22 February 2019, 9:41 AM
DOP59: What is the relationship between fatigue, pain and urgency in people with inflammatory bowel disease? Results of the IBD-BOOST survey in 8486 participants
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Hart, A.(1);Miller, L.(2);Hamborg, T.(2);Stagg, I.(1);McGuinness, S.(3);Wileman, V.(4);Tzorovili, E.(2);Mihaylova, B.(2);Roukas, C.(2);Aziz, Q.(5);Czuber-Dochan, W.(3);Dibley, L.(6);Moss-Morris, R.(7);Pollok, R.(8);Saxena, S.(9);Winsor, G.(10);Norton, C.(3)*;
Created: Friday, 14 July 2023, 10:43 AM
DOP60 Vedolizumab treatment persistence and safety in an extended access program (XAP)
Year: 2020
Source:

ECCO'20 Vienna

Authors:

S. Danese1, K. Subramanian2, J. Van Zyl3, S. Adsul4, D. Lindner5, J. Roth6, S. Vermeire7

Created: Thursday, 30 January 2020, 10:12 AM
DOP60: Environmental risk factors for Inflammatory bowel disease: A large prospective case-control study in India
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Banerjee, R.(1)*;Pal, P.(1);Prakash, N.(1);Mudigonda, S.(1);Joseph, S.(1);Patel, R.(1);Khalil, M.(1);Komawar, A.(1);Korikana, S.(1);Mekala, D.(1);Akki, Y.(1);Gaddam, A.(1);Valluri, S.(1);
Created: Friday, 14 July 2023, 10:43 AM
DOP60: Self-reported treatment effectiveness for Crohn's Disease using a novel crowdsourcing web-based platform
Year: 2022
Source: ECCO'22
Authors: Engel, T.(1);Dotan, E.(2);Ben-Horin, S.(1);Kopylov, U.(1);
Created: Friday, 11 February 2022, 3:52 PM
DOP60: Simplified rules to identify bio-naïve patients with Crohn’s Disease with higher likelihood of clinical remission when initiating vedolizumab versus anti-TNFα therapies: Analysis of EVOLVE study data
Year: 2021
Source: ECCO'21 Virtual
Authors: Mantzaris, G.(1);Yarur, A.(2);Wang, S.(3);Adsul, S.(4);Kamble, P.(4);Luo, M.(3);Guerin, A.(5);Billmyer, E.(5);Nguyen, H.(5);Bressler, B.(6)
Created: Wednesday, 2 June 2021, 4:12 PM
DOP60: The interleukin 22 transcriptional programme is activated in human colonic inflammation and associated to anti-TNFα primary non-response in Crohn’s
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

P. Pavlidis*1, A. Tsakmaki1, U. Niazi2, J. Digby-Bell1, G. Lombardi1, B. Hayee3, G. Bewick1, N. Powell1

Created: Friday, 22 February 2019, 9:41 AM
DOP61 Tofacitinib, an oral, small-molecule Janus kinase inhibitor, in the treatment of ulcerative colitis: Analysis of an open-label, long-term extension study with up to 5.9 years of treatment
Year: 2020
Source:

ECCO'20 Vienna

Authors:

G.R. Lichtenstein1, E.V. Loftus Jr2, S.C. Wei3, A.O. Damião4, D. Judd5, N. Lawendy5, G. Chan5, H. Zhang5, W. Wang5, A.J. Thorpe5, S. Bloom6

Created: Thursday, 30 January 2020, 10:12 AM
DOP61: A nationwide cohort study of colectomy rates for ulcerative colitis during the introduction of biologic therapy
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

G. Worley*1,2, A. Almoudaris1,2, P. Bassett3,4, J. Segal1,2, A. Akbar2,4, P. Aylin5, O. Faiz1,2

Created: Friday, 22 February 2019, 9:41 AM
DOP61: Development and validation of novel models in prediction of intravenous corticosteroids resistance in patients with Acute Severe Ulcerative Colitis
Year: 2022
Source: ECCO'22
Authors: Yu, S.(1);Li, H.(2);Li, Y.(1);Xu, H.(1);Tan, B.(1);Tian, B.(1);Dai, Y.(1);Tian, F.(2);Qian, J.(1);
Created: Friday, 11 February 2022, 3:52 PM
DOP61: Ethnic disparities in the management of Inflammatory Bowel Disease in Israel and impact on outcomes
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Boaz, E.(1)*;Ledder, O.(2);Dagan, A.(1);Lujan, R.(2);Koslowsky, B.(3);Friss, C.(2);Greenfeld, S.(4);Kariv, R.(4);Loewenberg Weisband , Y.(5);Lederman, N.(6);Matz, E.(7);Dotan, I.(8);Yellinek, S.(1);Turner, D.(2);
Created: Friday, 14 July 2023, 10:43 AM
DOP61: Impact of prior tumour necrosis factor inhibitor failure and prior corticosteroid use on the maintenance of efficacy of tofacitinib following dose reduction in patients with Ulcerative Colitis who were in stable remission: 6-month data from the double-blind, randomised RIVETING study
Year: 2021
Source: ECCO'21 Virtual
Authors: Sandborn, W.J.(1);Dubinsky, M.C.(2);Torres, J.(3);Vermeire, S.(4);Kotze, P.G.(5);Su, C.(6);Lawendy, N.(6);Paulissen, J.(7);Mundayat, R.(7);Gardiner, S.(7);Kulisek, N.(6);Modesto, I.(7);D’Haens, G.R.(8)
Created: Wednesday, 2 June 2021, 4:12 PM
DOP62 Morbidity after primary ileocecal resection for Crohn’s disease in the years of biologics: Lesson learned over 631 patients exclusively treated in a tertiary centre
Year: 2020
Source:

ECCO'20 Vienna

Authors:

M. Rottoli1, M. Tanzanu1, G. Vago1, A. Belvedere1, D. Parlanti1, P. Pezzuto1, S. Bosi1, F. Caputo1, F. Rizzello2, P. Gionchetti2, G. Poggioli1

Created: Thursday, 30 January 2020, 10:12 AM
DOP62: A novel formulation of CT-P13 (infliximab biosimilar) for subcutaneous administration: 1-year result from a Phase I open-label randomised controlled trial in patients with active Crohn’s disease
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

W. Reinisch*1, B. I. Jang2, V. Borzan3, A. Lahat4,5, A. Pukitis6, M. Osipenko7, Y. Mostovoy8, S. Schreiber9, S. Ben-Horin10, S. J. Lee11, J. H. Suh11, S. G. Lee11, J. H. Lee11, B. D. Ye12

Created: Friday, 22 February 2019, 9:41 AM
DOP62: Efficacy of biologic drugs in short-duration versus long-duration Inflammatory Bowel Disease: A systematic review and an individual-patient data meta-analysis of randomized controlled trials
Year: 2022
Source: ECCO'22
Authors: Ben-Horin, S.(1,2);Novack, L.(3);Mao, R.(2);Guo, J.(2);Zhao, Y.(2);Sergienko, R.(3);Zhang, J.(2);Kobayashi, K.(4);Hibi, T.(4);Chowers, Y.(5);Peyrin-Biroulet, L.(6);Colombel, J.F.C.(7);Kaplan, G.G.K.(8);Chen, M.H.(2);
Created: Friday, 11 February 2022, 3:52 PM
DOP62: Immunogenicity to second anti-TNF therapy (IMSAT): Implications for sequencing of biologic therapy
Year: 2021
Source: ECCO'21 Virtual
Authors: Chanchlani, N.(1);Lin, S.(1);Thomas, A.(1);Hamilton, B.(1);Nice, R.(2);Chee, D.(1);Kennedy, N.(1);Goodhand, J.(1);Ahmad, T.(1)
Created: Wednesday, 2 June 2021, 4:12 PM
DOP62: Medication use is increased in the decade prior to IBD diagnosis: A nationwide cohort study
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Bonfils, L.(1)*;Karachalia Sandri, A.(1);Juul Poulsen, G.(1);Agrawal, M.(1,2);Ward, D.J.(1);Jess, T.(1,3);Colombel, J.F.(2);H. Allin, K.(1,3);
Created: Friday, 14 July 2023, 10:43 AM
DOP63 Efficacy and safety of iron carboxymaltose on chronic fatigue in patients with inflammatory bowel disease: a randomised controlled trial
Year: 2020
Source:

ECCO'20 Vienna

Authors:

G. Fiorino1, M. Allocca1, D. Gilardi1, M. Alfieri1, P. Danieli1, F. Furfaro1, G. Roda1, L. Loy1, A. Zilli1, S. Radice1, L. Peyrin-Biroulet2, S. Danese1

Created: Thursday, 30 January 2020, 10:12 AM